Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study
Talquetamab(一种GPRC5D×CD3双特异性抗体)治疗中国复发/难治性多发性骨髓瘤患者的疗效和安全性:来自MonumentTAL-1 1/2期研究
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2025.287334
An, Gang; Jin, Jie; Cai, Zhen; Jing, Hongmei; Fu, Chengcheng; He, Pengcheng; Xia, Zhongjun; Liu, Rui; Li, Liang; Gai, Xue; Zhang, Hong; Zhu, Dian; Luo, Xinchao; Sun, Binbin; Xu, Hongmei; Zhou, Longen; Campagna, Michela; Masterson, Tara J; Lau, Bonnie W; Renaud, Thomas; Heuck, Christoph; Singh, Indrajeet; Vishwamitra, Deeksha; Qiu, Lugui